Search company, investor...



Series A | Alive

About Neomics

Neomics is a drug discovery and diagnostics company with a unique cancer target and biomarker discovery platform. In particular, Neomics is focused on novel targets and biomarkers relevant to aminoacyl RNA synthetases (ARS). They have preclinical and clinical validation of their targets and biomarkers.

Headquarters Location

864-1 Iui-dong Youngtong-gu Suwon-si


South Korea

+82-31-888-9933 or 9955

Missing: Neomics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Neomics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Neomics Patents

Neomics has filed 1 patent.

The 3 most popular patent topics include:

  • Cell biology
  • Clusters of differentiation
  • Food ingredients
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Transcription factors, Food ingredients, Cell biology, Human proteins


Application Date


Grant Date



Related Topics

Clusters of differentiation, Transcription factors, Food ingredients, Cell biology, Human proteins



Latest Neomics News

Neomics Co.Ltd., first recipient of Norvatis" Korea Fund

May 18, 2016

You are a  user. The feature you are trying to access  Subscribers. Please Register to access this feature or log in if you are a Subscriber, or if you have already Registered. Please click the following link to register and submit an upgrade request, so that a member of our sales team can contact you to discuss your requirements. Please click the 'Request Upgrade' button to log your details so that a member of our sales team can contact you to discuss your additional requirements. Your request to access this feature is pending. You have already logged a callback request. A member of our team will contact you to discuss your access level. This feature is not yet available. We have already attempted to contact you following your recent request. We will try and call you again shortly but in the meantime please check that your contact details are correct and up to date or if you prefer please contact us. View My Contact Details    Contact Us Retrieving... EP Vantage brings a fresh view on pharma and biotech with incisive daily analysis, powered by Evaluate Ltd. You are a subscriber to the full Evaluate Ltd. service. Click here to login to the subscribers' welcome page. Don't remind me again You are currently accessing our secondary server Although the site contains up to date data, some features are unfortunately not available on the secondary server. We apologise for any inconvenience this may cause. Close ECommerce Support If you would prefer to speak to a member of our sales team please call us on +44 (0)20 7377 0800 Alternatively, if you are experiencing problems with an existing order a member of our support team will be happy to assist you. Call +44 (0)20 7377 0800 Telephone lines are open Mon - Fri 9am - 5pm London Time. Alternatively, send an email to Shopping Cart Fetching cart contents. Please wait. Please register your details with us to complete your purchase or click Login if you have already registered with us.    

Neomics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Neomics Rank

Neomics Frequently Asked Questions (FAQ)

  • Where is Neomics's headquarters?

    Neomics's headquarters is located at 864-1 Iui-dong, Gyeonggi-do.

  • What is Neomics's latest funding round?

    Neomics's latest funding round is Series A.

  • Who are the investors of Neomics?

    Investors of Neomics include Novartis Venture Funds.

  • Who are Neomics's competitors?

    Competitors of Neomics include Phico Therapeutics, Momenta Pharmaceuticals, Igenica Biotherapeutics, MabVax Therapeutics, Sopherion and 10 more.

Compare Neomics to Competitors


Sopherion is a therapeutics platform company initially focused on cancer.

Falcon Genomics

Falcon Genomics, Inc. is focused on functional genomics as a tool for cancer diagnostics and therapeutics.

Progression Therapeutics

Progression Therapeutics is a biotechnology company focused on the treatment of primary and metastatic cancer. The Company currently has multiple products in various stages of evaluation, including a tumor suppressor gene product that has demonstrated potent anti-tumor activity both in vitro and in vivo.

Avidimer Therpeutics

Avidimer Therapeutics is engaged in the discovery and development of therapeutics for inflammatory diseases

Immunomic Therapeutics Logo
Immunomic Therapeutics

Immunomic Therapeutics operates as a development-stage biotechnology company focusing on the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. The company develops lysosomal-associated membrane protein-based vaccines for the treatment of allergies and other human health targets. It was founded in 2005 and is based in Rockville, Maryland.


Eximias is developing late stage cancer therapeutics. Eximias is now a wholly-owned subsidiary of YM named YM BioSciences USA

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.